Axitinib is Used for the treatment of advanced renal cell carcinoma, typically in combination with other medications like avelumab or pembrolizumab. It was first introduced by Pf Prism Cv in its drug Inlyta on Jan 27, 2012.

Axitinib Patents

Given below is the list of patents protecting Axitinib, along with the drug name that holds that patent and the company name owning that drug.

Download patent list as spreadsheet

Get the complete list right in your inbox!

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Inlyta	US10869924 (Pediatric)	PD-L1 antagonist combination treatments	Jul 12, 2037	Pf Prism Cv
Inlyta	US10869924	PD-L1 antagonist combination treatments	Jan 12, 2037	Pf Prism Cv
Inlyta	US10570202 (Pediatric)	Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer	Aug 03, 2035	Pf Prism Cv
Inlyta	US10570202	Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer	Feb 03, 2035	Pf Prism Cv
Inlyta	US8791140 (Pediatric)	Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyondazole suitable for the treatment of abnormal cell growth in mammals	Jun 14, 2031	Pf Prism Cv
Inlyta	US8791140	Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyondazole suitable for the treatment of abnormal cell growth in mammals	Dec 14, 2030	Pf Prism Cv
Inlyta	US6534524 (Pediatric)	Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use	Oct 29, 2025	Pf Prism Cv
Inlyta	US6534524	Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use	Apr 29, 2025 (Expired)	Pf Prism Cv
Inlyta	US7141581	Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use	Jun 30, 2020 (Expired)	Pf Prism Cv

Add above patents to watchlist

Axitinib's Family Patents

Full family tree